Skip to main content

Table 2 Association between clinicopathologic features and KPNA2 protein expression

From: Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer

KPNA2 expression

 

n

Negative

Weak

Positive

p-value

Age (years)

    

0.746

  < 65

78

22 (28.2)

36 (46.2)

20(25.6)

 

  ≥ 65

117

37 (31.6)

47 (40.2)

33 (28.2)

 

Sex

    

0.665

 Male

83

25 (30.1)

33 (39.8)

25 (30.1)

 

 Female

112

34 (30.4)

50 (44.6)

28 (25.0)

 

Location

    

0.664

 Right

82

21(25.6)

37 (45.1)

24 (29.3)

 

 Transverse

18

9 (50.0)

7 (38.9)

2 (11.1)

 

 Descendent

18

5 (27.8)

7(38.9)

6 (33.3)

 

 Left

77

25(32.5)

32 (41.6)

20 (26.0)

 

AJCC stage

    

0.01*

 I

22

12 (54.5)

7 (31.8)

3 (13.6)

 

 II

79

25 (31.6)

37 (46.8)

17 (21.5)

 

 III

76

21 (27.6)

30 (39.5)

25 (32.9)

 

 IV

18

1 (5.6)

8 (44.4)

9 (50.0)

 

N stage

    

0.025*

 N0

104

40 (38.5)

45 (43.3)

19 (18.3)

 

 N1

57

14 (24.6)

22 (38.6)

21 (36.8)

 

 N2

34

6 (17.6)

15 (44.1)

13 (38.2)

 

M stage

    

0.014*

 M0

177

58 (32.8)

75 (42.4)

44 (24.9)

 

 M1

18

1 (5.6)

8 (44.4)

9 (50.0)

 

T stage

    

0.018*

 T1 + T2

28

14 (50.0)

12 (42.9)

2 (7.1)

 

 T3 + T4

167

46 (27.5)

71 (42.5)

50 (30.0)

 

Differentiation

    

0.001*

 High

97

39 (40.2)

41 (42.3)

17 (17.5)

 

 Moderate

68

13 (19.1)

33 (48.5)

22 (32.4)

 

 Low

30

8 (26.7)

8 (26.7)

14 (46.7)

 

Vascular invasion

    

0.604

 Yes

14

3 (21.4)

8 (57.1)

3 (21.4)

 

 No

181

56 (30.9)

75 (41.4)

50 (27.6)

 

Ki-67 expression

    

0.002*

 Negative

36

11 (30.6)

22 (61.1)

3 (8.3)

 

 Positive

159

48 (30.2)

60 (37.8)

50 (31.4)

 
  1. *p < 0.005 indicates a significant association between the variables